Skip to main content
Erschienen in: Acta Diabetologica 1/2012

01.12.2012 | Original Article

Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus

verfasst von: Chih-Min Chang, Ching-Jung Hsieh, Ju-Chun Huang, I-Chin Huang

Erschienen in: Acta Diabetologica | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

In order to investigate whether short- or long-term glycemic fluctuations could induce oxidative stress and chronic inflammation, we evaluated the relationships between glycemic variability, oxidative stress markers, and high-sensitivity C-reactive protein (hs-CRP). We enrolled 34 patients with type 2 diabetes. As a measure of short-term glycemic variability, mean amplitude of glycemic excursions (MAGE) was computed from continuous glucose monitoring system data. For determining long-term glycemic variability, we calculated the standard deviation (SD) of hemoglobin A1c (HbA1c) levels measured over a 2-year period. Levels of oxidative stress markers: 8-iso-prostaglandin F2α (8-iso-PGF2α), thiobarbituric acid-reactive substance (TBARS), 8-hydroxydeoxyguanosine (8-OHdG), and hs-CRP were measured. MAGE was significantly correlated with the SD of HbA1c levels (r = 0.73, p < 0.001) but not with HbA1c level. The levels of hs-CRP, TBARS, 8-OHdG, and 8-iso-PGF2α were significantly correlated with MAGE (r = 0.54, p = 0.001; r = 0.82, p < 0.001; r = 0.70, p < 0.001; r = 0.60, p < 0.001) and the SD of HbA1c levels (r = 0.53, p = 0.001; r = 0.73, p < 0.001; r = 0.69, p < 0.001; r = 0.43, p = 0.01) but not with HbA1c level. Relationships between 8-iso-PGF2α and MAGE or the SD of HbA1c levels remained significant after adjusting for other markers of diabetic control (R 2 = 0.684, R 2 = 0.595, p < 0.001, respectively). Both acute and chronic blood glucose variability can induce oxidative stress and chronic inflammation.
Literatur
1.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA et al, UK Prospective Diabetes Study Group (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405–412 Stratton IM, Adler AI, Neil HA et al, UK Prospective Diabetes Study Group (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405–412
2.
Zurück zum Zitat Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular disease. J Hypertens 18:655–673PubMedCrossRef Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular disease. J Hypertens 18:655–673PubMedCrossRef
3.
Zurück zum Zitat Harrison D, Griendling KK, Landmesser U et al (2003) Role of oxidative stress in atherosclerosis. Am J Cardiol 91:7A–11APubMedCrossRef Harrison D, Griendling KK, Landmesser U et al (2003) Role of oxidative stress in atherosclerosis. Am J Cardiol 91:7A–11APubMedCrossRef
4.
Zurück zum Zitat Brownlee M (2005) The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef Brownlee M (2005) The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef
5.
Zurück zum Zitat Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
6.
Zurück zum Zitat Monnier L, Colette C, Boniface H (2006) Contribution of postprandial glucose to chronic hyperglycemia: from the ‘glucose triad’ to the trilogy of ‘sevens’. Diabetes Metab 32:2S12–2S17 Monnier L, Colette C, Boniface H (2006) Contribution of postprandial glucose to chronic hyperglycemia: from the ‘glucose triad’ to the trilogy of ‘sevens’. Diabetes Metab 32:2S12–2S17
7.
Zurück zum Zitat Derr R, Garrett E, Stacy GA, Saudek CD (2003) Is HbA1c Affected by glycemic instability? Diabetes Care 26:2728–2733PubMedCrossRef Derr R, Garrett E, Stacy GA, Saudek CD (2003) Is HbA1c Affected by glycemic instability? Diabetes Care 26:2728–2733PubMedCrossRef
8.
Zurück zum Zitat Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef
9.
Zurück zum Zitat Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diab Tologia 50:2280–2288CrossRef Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diab Tologia 50:2280–2288CrossRef
10.
Zurück zum Zitat Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH (2010) Review glucose variability; does it matter? Endocr Rev 31:171–182PubMedCrossRef Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH (2010) Review glucose variability; does it matter? Endocr Rev 31:171–182PubMedCrossRef
11.
Zurück zum Zitat Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H (2007) Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 33:247–252PubMedCrossRef Monnier L, Colette C, Boegner C, Pham TC, Lapinski H, Boniface H (2007) Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 33:247–252PubMedCrossRef
12.
Zurück zum Zitat Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef
13.
Zurück zum Zitat Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef
14.
Zurück zum Zitat Kohnert KD, Augstein P, Zander E et al (2009) Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32:1058–1062PubMedCrossRef Kohnert KD, Augstein P, Zander E et al (2009) Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32:1058–1062PubMedCrossRef
15.
Zurück zum Zitat Roberts LJ, Morrow JD (2000) Measurement of F (2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505–513PubMedCrossRef Roberts LJ, Morrow JD (2000) Measurement of F (2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505–513PubMedCrossRef
16.
Zurück zum Zitat Morrow JD (2000) The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:377–385PubMedCrossRef Morrow JD (2000) The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:377–385PubMedCrossRef
17.
Zurück zum Zitat Davi G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229PubMedCrossRef Davi G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229PubMedCrossRef
18.
Zurück zum Zitat Minuz P, Patrignani P, Gaino S et al (2002) Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106:2800–2805PubMedCrossRef Minuz P, Patrignani P, Gaino S et al (2002) Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106:2800–2805PubMedCrossRef
19.
Zurück zum Zitat Davi G, Guagnano MT, Ciabattoni G et al (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288:2008–2014PubMedCrossRef Davi G, Guagnano MT, Ciabattoni G et al (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288:2008–2014PubMedCrossRef
20.
Zurück zum Zitat Monnier L, Colette C, Mas E et al (2010) Regulation of oxidative stress by glycemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562–571PubMedCrossRef Monnier L, Colette C, Mas E et al (2010) Regulation of oxidative stress by glycemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562–571PubMedCrossRef
21.
Zurück zum Zitat Pan HZ, Zhang L, Guo MY et al (2010) The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 47(suppl 1):71–76PubMedCrossRef Pan HZ, Zhang L, Guo MY et al (2010) The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 47(suppl 1):71–76PubMedCrossRef
22.
Zurück zum Zitat Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, Fasanmade A, Moropane M (2008) Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J 98:614–617PubMed Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, Fasanmade A, Moropane M (2008) Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J 98:614–617PubMed
23.
Zurück zum Zitat Quagliaro L, Piconi L, Assalone R, Martinelli L, Motz E, Ceriello A (2003) Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-Oxidase activation. Diabetes 52:2795–2804PubMedCrossRef Quagliaro L, Piconi L, Assalone R, Martinelli L, Motz E, Ceriello A (2003) Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-Oxidase activation. Diabetes 52:2795–2804PubMedCrossRef
24.
Zurück zum Zitat Hsieh CJ, Weng SW, Liou CW et al (2011) Tissue-specific differences in mitochondrial DNA content in type 2 diabetes. Diabetes Res Clin Pract 92:106–110PubMedCrossRef Hsieh CJ, Weng SW, Liou CW et al (2011) Tissue-specific differences in mitochondrial DNA content in type 2 diabetes. Diabetes Res Clin Pract 92:106–110PubMedCrossRef
25.
Zurück zum Zitat Amanullah S, Jarari A, Govindan M, Basha MI, Khatheeja S (2010) Association of hs-CRP with diabetic and non-diabetic individuals. Jordan J Biol Sci 3:7–12 Amanullah S, Jarari A, Govindan M, Basha MI, Khatheeja S (2010) Association of hs-CRP with diabetic and non-diabetic individuals. Jordan J Biol Sci 3:7–12
26.
Zurück zum Zitat Huang IC, Wang PW, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh CJ (2012) The influence of self-monitoring blood glucose frequency on the oscillation of hemoglobulin A1c and chronic complications. Chang Gung Med 35:46–53 Huang IC, Wang PW, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh CJ (2012) The influence of self-monitoring blood glucose frequency on the oscillation of hemoglobulin A1c and chronic complications. Chang Gung Med 35:46–53
27.
Zurück zum Zitat Choi SW, Benzie I, Ma SW, Strain JJ, Hannigan BM (2008) Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 44:1217–1231PubMedCrossRef Choi SW, Benzie I, Ma SW, Strain JJ, Hannigan BM (2008) Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 44:1217–1231PubMedCrossRef
28.
Zurück zum Zitat Hirsch IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat 19:178–181PubMedCrossRef Hirsch IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complicat 19:178–181PubMedCrossRef
29.
Zurück zum Zitat Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH (2008) Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183–190PubMedCrossRef Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH (2008) Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183–190PubMedCrossRef
30.
Zurück zum Zitat Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries HJ (2011) No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 5:86–92PubMed Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries HJ (2011) No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 5:86–92PubMed
Metadaten
Titel
Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus
verfasst von
Chih-Min Chang
Ching-Jung Hsieh
Ju-Chun Huang
I-Chin Huang
Publikationsdatum
01.12.2012
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe Sonderheft 1/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-012-0398-x

Weitere Artikel der Sonderheft 1/2012

Acta Diabetologica 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.